Harnessing Targeted Protein Degradation for Developing Brain Cancer Therapy

Area of Science:

• Oncology
• Neuroscience
• Drug Discovery

Background:

• Brain neoplasms present significant treatment challenges due to tumor heterogeneity and the brain's immune-privileged status.
• Conventional small molecule inhibitors often show incomplete efficacy because of pathway redundancy and compensatory mechanisms.
• Induced protein degradation is an emerging therapeutic strategy with a novel mechanism of action.

Purpose of the Study:

• To review the current landscape of protein degradation technologies for brain cancer therapy.
• To focus on Proteolysis-Targeting Chimeras (PROTACs), molecular glues, and Lysosome-Targeting Chimeras (LYTACs).
• To discuss the synthesis, biological evaluation, and translational potential of these degradation modalities.

Main Methods:

• Literature review of protein degradation technologies.
• Focus on PROTACs, molecular glues, and LYTACs in the context of brain cancer.
• Analysis of synthesis, biological evaluation, and translational aspects.

Main Results:

• Protein degradation offers a promising approach to overcome limitations of conventional therapies for brain tumors.
• PROTACs, molecular glues, and LYTACs are key modalities with potential therapeutic applications.
• These technologies are advancing towards clinical trials for various cancers, including brain neoplasms.

Conclusions:

• Protein degradation technologies represent a significant advancement in the development of novel brain cancer therapies.
• The field holds promise for overcoming treatment resistance and improving patient outcomes.
• Breakthroughs in induced protein degradation could transform the therapeutic landscape for brain cancer patients.